Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Feb 08, 2026
BSX vs MDT vs SYK: MedTech Earnings Preview as Q4 Results Put Growth and Margins in Focus

BSX vs MDT vs SYK: MedTech Earnings Preview as Q4 Results Put Growth and Margins in Focus

Key Takeaways

  • Boston Scientific (BSX) reports Q4 2025 earnings on February 4, with consensus expecting $0.78 adjusted EPS on $5.27B revenue, in line with guidance of $0.77–$0.79 EPS and 11–13% organic growth.

  • Medtronic (MDT) posted strong Q2 FY26 results: $9B revenue (+5.5% organic), $1.36 adjusted EPS, raising FY26 guidance amid pulsed field ablation momentum. Q3 FY26 results are expected February 17.

  • Stryker (SYK) delivered record Q4/FY 2025 results: $7.17B Q4 revenue (+11% organic), $4.47 adjusted EPS; FY sales topped $25B with 2026 guidance of 8–9.5% organic growth.

  • BSX leads in cardiovascular and MedSurg growth, while MDT and SYK focus on stable margins and capital equipment strength.

  • All three benefit from procedural volume recovery, though tariff headwinds (~$185–$400M impact) loom for 2026.

  • Investor focus: BSX’s strong beat history (~7% average) vs. peers’ raised outlooks signals competitive positioning.

Why This Comparison Matters

Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.

MDT’s ablation surge and SYK’s Mako robotics dominance illustrate trade-offs between growth and scale. Combined, the trio represents ~$300B in market capitalization, offering investors insight into cardiovascular, orthopedics, and surgical trends amid 8–10% industry growth forecasts.

BSX Earnings Focus

  • Revenue: $5.27B (+15.6% YoY, 11–13% organic per guidance)

  • Adjusted EPS: $0.78 (+11% YoY), within company guidance of $0.77–$0.79

  • Key drivers:

    • Cardiovascular (~65% revenue): FARAPULSE PFA, WATCHMAN FLX

    • MedSurg: Neuromodulation post-Axonix

    • U.S. revenue: ~$3.39B expected (+17%)

  • Other metrics: Margin pressure from tariffs, historical EPS beats ~7.36% average, FY25 EPS raised to $3.02–$3.04

  • Stock reaction: Historically +3–4% on positive surprises

MDT Earnings/Business Context

  • Q2 FY26 results: $9B revenue (+5.5% organic), $1.36 adjusted EPS (+8%)

  • Cardiac ablation: 71% growth (U.S. PFA +128%)

  • FY26 guidance: 5.5% organic revenue growth, EPS $5.62–$5.66

  • Margins: Adjusted gross margin +70bps to 65.9%

  • Risks: Tariff impacts (~$185M FY26), China VBP pressures

  • Outlook: Scale and diversification provide stability vs. BSX’s higher-growth trajectory

SYK Earnings/Business Context

  • Q4/FY 2025 results: $7.17B Q4 revenue (+11% organic), $4.47 adjusted EPS (+11.5%); FY $25.12B revenue (+10.3% organic), $13.63 EPS (+11.8%)

  • Margins: Adjusted operating margin +100bps to 26.3%; free cash flow 81% of adjusted net earnings

  • 2026 guidance: 8–9.5% organic growth, $14.90–$15.10 EPS

  • Drivers: Mako robotics (orthopedics), double-digit MedSurg/Neuro growth, vascular pressures manageable

  • Risks: Tariffs (~$400M), supply chain, orthopedics competition

  • Positioning: Procedural and capital equipment focus contrasts BSX’s interventional emphasis

AI Trading Bot Perspective

Tickeron offers AI-driven trading bots for BSX, MDT, and SYK:

  • BSX bot: Trend Trader for Broad Market Optimal Financial Fusion (60min FA), targeting large-cap trend momentum

  • MDT bot: Corridor TP-SL 2 AI Agent (60min), optimized for channel-based entries/exits

  • SYK bot: Trend Trader for Beginners (60min TA), ideal for orthopedic momentum plays

Historical performance varies by market conditions; these bots provide automated signals to complement manual analysis.

Key DriversCardio & MedSurgCardio & scaleOrtho/Capital equipment

  • BSX: High-growth cardiovascular, potential upside from historical beats

  • MDT: Broad therapy stability, slower growth but reliable margins

  • SYK: Ortho/surgical dominance with strong margin expansion

  • Risks: BSX procedure-sensitive; MDT China & tariffs; SYK supply/ortho competition

Investor sentiment tilts BSX for growth, peers for stability, reflecting trade-offs between upside potential vs. steady execution.

Tickeron AI Verdict

Tickeron’s AI models currently favor BSX pre-earnings, citing:

  • Superior trend stability

  • 15%+ organic trajectory

  • Historical EPS beat consistency

MDT and SYK provide lower-volatility, steady profiles, but BSX holds a probabilistic edge if guidance is reaffirmed and tariffs remain manageable.

Disclaimers and Limitations

Related Ticker: BSX, SYK, MDT

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


BSX's Indicator enters downward trend

The Aroon Indicator for BSX entered a downward trend on October 13, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 136 similar instances where the Aroon Indicator formed such a pattern. In 91 of the 136 cases the stock moved lower. This puts the odds of a downward move at 67%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 48 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.

BSX moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BSX crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 47%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BSX's RSI Indicator exited the oversold zone, 17 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 28 of 51 cases where BSX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 55%.

The Moving Average Convergence Divergence (MACD) for BSX just turned positive on October 12, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in 22 of 45 cases over the following month. The odds of a continued upward trend are 49%.

Following a +4.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 200 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.

BSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.564) is normal, around the industry mean (10.930). P/E Ratio (17.858) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 5.59B. The market cap for tickers in the group ranges from 837 to 174.73B. ABT holds the highest valuation in this group at 174.73B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -4%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was -15%. PMI experienced the highest price growth at 75%, while NXL experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -19% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 73
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 95
Seasonality Score: 10 (-100 ... +100)
View a ticker or compare two or three
BSX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of medical devices

Industry MedicalNursingServices

Industry
Medical Specialties
Address
300 Boston Scientific Way
Phone
+1 508 683-4000
Employees
59000
Web
https://www.bostonscientific.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.